Paper Details

  1. Home
  2. Paper Details

Comparative efficacy and safety of cefprozil and cefaclor in the treatment of acute uncomplicated urinary tract infections.

Author: ChristensonJ C, GoochW M, HerrodJ N, SwensonE

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Cefprozil, a new oral cephalosporin, was found to be as effective as cefaclor in treating acute, uncomplicated urinary tract infections. In a study of 98 patients, clinical and bacteriological responses were comparable for both antibiotics. Leucopenia, nausea, and vaginal yeast infections were slightly more common in the cefprozil group.
Paper Details　
Original Abstract of the Article :
Cefprozil is a new oral semi-synthetic cephalosporin with broad antibacterial spectrum and prolonged serum elimination half-life. In vitro, cefprozil demonstrates excellent activity against common urinary tract pathogens such as Escherichia coli and Klebsiella pneumoniae. Cefprozil, 500 mg once a da...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/28.4.581

データ提供：米国国立医学図書館（NLM）

Cefprozil: A Refreshing Oasis in the Desert of Urinary Tract Infections

The landscape of [urinary tract infections (UTIs)] can be a challenging desert, with many individuals experiencing discomfort, pain, and difficulty navigating this ailment. This research, like a seasoned guide leading a caravan through this arid terrain, explores the effectiveness of [ceprozil], a new antibiotic for treating UTIs. The study, conducted as a [randomized, comparative clinical trial], aimed to determine whether cefprozil was as effective as [cefaclor], a well-established antibiotic for UTIs. The researchers compared the [clinical and bacteriological responses] of patients treated with each antibiotic, assessing their efficacy and tolerability in this challenging setting.

A Comparative Oasis in the Desert of UTI Treatment

The study found that [ceprozil was comparable to cefaclor in its effectiveness in treating UTIs], providing valuable insights into the efficacy of this new antibiotic. The finding that [clinical and bacteriological responses were comparable for both antibiotics] is particularly encouraging, suggesting that cefprozil is a viable alternative for patients who may not tolerate cefaclor. This finding is like discovering a hidden oasis in the desert, offering hope for a new path forward in the treatment of UTIs.

Navigating the Desert of UTI Treatment with Cefprozil

This research highlights the potential of cefprozil as an effective treatment option for UTIs, offering a valuable tool for healthcare professionals. Just as a camel adapts to the desert environment, we must continue to explore and utilize new technologies and therapies to combat this challenging disease. Remember, the desert of UTIs can be vast and complex, and finding the right tools and techniques for managing the disease is essential for well-being.

Dr.Camel's Conclusion

This research provides evidence that cefprozil is an effective treatment option for urinary tract infections, offering a valuable tool for healthcare professionals and patients alike. Like a camel navigating the shifting sands of the desert, researchers continue to adapt and seek new solutions to combat the challenges of UTIs. This new antibiotic offers a beacon of hope in the desert of UTI treatment, providing a path toward improved outcomes for patients.

Date :
  1. Date Completed 1992-02-13
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

1761453

DOI: Digital Object Identifier

10.1093/jac/28.4.581

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.